Williamson et al. (2012) showed that mantle cell lymphoma expressing ATM and p53 mutations exhibit enhanced cytotoxicity to olaparib (PARP inhibitor) treatment both in vitro and in vivo [119]. Here, PARP1 is linked to mantle cell lymphoma.